NCT07533305尚未招募2 期
A Single-arm Clinical Study of QL1706 (Anti PD-1 and CTLA-4 Antibody) in Combination With Nab-paclitaxel and Cisplatin as First-line Therapy in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Henan University of Science and Technology0 个研究点目标入组 50 人开始时间: 2026年5月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 主要终点
- ORR
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. QL1706 is a anti-PD-1 and anti-CTLA4 antibody.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects participate voluntarily and sign informed consent.
- •18-75 years, male or female.
- •Histologically confirmed Unresectable Advanced or metastatic Esophageal Squamous Cell Carcinomas
- •No previous systemic anti-tumor treatment for unresectable locally advanced or metastatic esophageal squamous cell carcinoma has been received
- •At least 1 measurable target lesion and/or unmeasurable target lesion according to Response Evaluation in Solid Tumors (RECIST 1.1).
- •ECOG PS 0-1
- •Expected survival ≥ 12 weeks
- •Adequate organ function (without blood transfusion or growth factors within 14 days prior to first dose), including: ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum albumin ≥ 30 g/L; Total bilirubin ≤ 1.5 × ULN; ALT/AST ≤ 2.5 × ULN (≤ 5 × ULN if with liver or bone metastases); ALP ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN; INR ≤ 1.5 (if not on anticoagulation);
- •Non-sterilized women of childbearing potential and male participants with such partners must agree to use medically approved contraception during and for 3 months after study drug administration. Women must test negative for serum or urine HCG within 7 days prior to first dose and not be breastfeeding
排除标准
- •Have received anti-PD-1 or anti-PD-L1 antibody therapy;
- •BMI < 18.5 kg/m2 or weight loss ≥ 10% within 2 months before screening (at the same time, the effect of a large amount of pleural effusions and ascites on bogy weight should be considered);
- •Presence of any active autoimmune disease or history of autoimmune disease (such as: Autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism)
- •Those who are taking immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (dose> 10 mg/day prednisone or other equivalent cortiremonial hormones)
- •Severe allergic reaction to other monoclonal antibodies
- •Known history or evidence of interstitial lung disease or active non-infectious pneumonia
- •Known central nervous system metastases
- •History of other malignancies within the past 5 years or concurrent malignancies (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).
- •Uncontrolled cardiac clinical symptoms or diseases, such as: (1) NYHA class II or higher heart failure (2) unstable angina (3) myocardial infarction within the past year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) QTc > 450 ms (male); QTc > 470 ms (female)
- •Tumor invasion of major blood vessels, or based on imaging, the investigator determines a high likelihood of tumor invasion of major blood vessels during the study period, which may lead to fatal bleeding, such as imaging evidence of >90-degree encasement of major vessels or tumor cavitation
- •Patients with pleural effusion, ascites, or pericardial effusion requiring drainage; if the symptoms are stable after drainage as assessed by the investigator, enrollment is possible. Gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the start of study treatment.
- •Major surgical procedures within 4 weeks prior to the start of study treatment (diagnostic procedures excluded) or anticipated need for major surgery during the study period.
- •Active infection, unexplained fever ≥38.5°C within 7 days prior to drug administration, or baseline white blood cell count >15×109/L.
- •Congenital or acquired immunodeficiency (e.g., HIV infection); hepatitis B surface antigen (HBsAg) positive with hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥2000 IU/ml, or positive for hepatitis C virus antibody.
- •Live vaccine administration within 4 weeks prior to study drug administration or during the study period.
- •As judged by the investigator, other factors that may affect study outcomes or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases (including psychiatric disorders) requiring concurrent treatment, significant laboratory abnormalities, or family or social factors that may impact patient safety.
研究组 & 干预措施
QL1706 plus nab-paclitaxel and cisplatin
Experimental
干预措施: QL1706 plus nab-paclitaxel and cisplatin (Drug)
结局指标
主要结局
ORR
时间窗: From the date of first dose to achieving complete response or partial response, assessed up to 42 months
ORR is defined as the percentage of participants with Complete Response or Partial Response per RECIST 1.1 assessed by the investigators.
次要结局
- PFS(From the date of first dose to the date of first documented progression or death from any cause, whichever occurs first, assessed up to 42 months.)
- OS(From the date of first dose to the date of death due to any cause, assessed up to 48months.)
- DOR(From the date of first documented evidence of CR or PR to the date of PD or death, assessed up to 42 months.)
- number of participants with AEs(From first dose to the later of 90 days after the last dose of QL1706 or 30 days after the last dose of nab-paclitaxel or cisplatin, assessed up to 48 months.)
研究者
Shan TY
Professor
The First Affiliated Hospital of Henan University of Science and Technology
相似试验
招募中
2 期
QL1706 Plus Lenvatinib in Previously Treated Penile CancerPenile CancerNCT07384416Sun Yat-sen University47
招募中
2 期
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerNCT07481058Beijing Konruns Pharmaceutical Co., Ltd.60
尚未招募
2 期
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast CancerNCT07256964Henan Cancer Hospital216
招募中
2 期
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.NCT07410520The First Affiliated Hospital with Nanjing Medical University50
尚未招募
2 期
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)NCT07471165The First Affiliated Hospital with Nanjing Medical University25